Hormone receptors in breast cancer

K. Seibert, Marc E Lippman

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Many advance have been made in the field of steroid receptor science and its application to new treatment approaches. The gaps in our knowledge of receptor mechanisms have narrowed over the past decade. Some gaps remain to be bridged, as, for example, in the area of nuclear acceptor sites for ER. The total import and role of some receptors, such as prolactin and vitamin D receptors, have yet to be clarified. The DCC assay remains the most practical method for the clinical evaluation of ER and PR status in samples from most postmenopausal women. Samples from premenopausal patients, or patients on tamoxifen therapy, should be evaluated by means of a suitable exchange assay, such as the hydroxylapatite method. Histochemical assays, while more rapid and convenient than the standard DCC or hydroxylapatite assay, have not been fully standardized and have not yet been proved to be a reliable alternative to more conventional techniques. However, they offer promise for a more convenient method of receptor evaluation in the future. The ER and PR status of a tumour, while not absolutely predictive, may serve as an aid in planning treatment for breast cancer patients. ER-negative patients do not benefit significantly from endocrine therapy, while approximately 50 per cent of patients with ER-positive tumours respond to hormonal manipulation. Hyposectomy and adrenalectomy are not largely historical therapies. Presently, endocrine therapies should be used selectively and with good judgement. Tamoxifen, other promising antioestrogens and aminoglutethemide given alone or in combination with other cemotherapeutic agents will play an increasing role in the therapy of breast cancer.

Original languageEnglish
Pages (from-to)735-794
Number of pages60
JournalClinics in Oncology
Volume1
Issue number3
StatePublished - Dec 1 1982
Externally publishedYes

Fingerprint

Hormones
Breast Neoplasms
Tamoxifen
Durapatite
Therapeutics
Calcitriol Receptors
Estrogen Receptor Modulators
Steroid Receptors
Adrenalectomy
Prolactin
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Seibert, K., & Lippman, M. E. (1982). Hormone receptors in breast cancer. Clinics in Oncology, 1(3), 735-794.

Hormone receptors in breast cancer. / Seibert, K.; Lippman, Marc E.

In: Clinics in Oncology, Vol. 1, No. 3, 01.12.1982, p. 735-794.

Research output: Contribution to journalArticle

Seibert, K & Lippman, ME 1982, 'Hormone receptors in breast cancer', Clinics in Oncology, vol. 1, no. 3, pp. 735-794.
Seibert K, Lippman ME. Hormone receptors in breast cancer. Clinics in Oncology. 1982 Dec 1;1(3):735-794.
Seibert, K. ; Lippman, Marc E. / Hormone receptors in breast cancer. In: Clinics in Oncology. 1982 ; Vol. 1, No. 3. pp. 735-794.
@article{9289bd830fd34174afcceed1c31c2add,
title = "Hormone receptors in breast cancer",
abstract = "Many advance have been made in the field of steroid receptor science and its application to new treatment approaches. The gaps in our knowledge of receptor mechanisms have narrowed over the past decade. Some gaps remain to be bridged, as, for example, in the area of nuclear acceptor sites for ER. The total import and role of some receptors, such as prolactin and vitamin D receptors, have yet to be clarified. The DCC assay remains the most practical method for the clinical evaluation of ER and PR status in samples from most postmenopausal women. Samples from premenopausal patients, or patients on tamoxifen therapy, should be evaluated by means of a suitable exchange assay, such as the hydroxylapatite method. Histochemical assays, while more rapid and convenient than the standard DCC or hydroxylapatite assay, have not been fully standardized and have not yet been proved to be a reliable alternative to more conventional techniques. However, they offer promise for a more convenient method of receptor evaluation in the future. The ER and PR status of a tumour, while not absolutely predictive, may serve as an aid in planning treatment for breast cancer patients. ER-negative patients do not benefit significantly from endocrine therapy, while approximately 50 per cent of patients with ER-positive tumours respond to hormonal manipulation. Hyposectomy and adrenalectomy are not largely historical therapies. Presently, endocrine therapies should be used selectively and with good judgement. Tamoxifen, other promising antioestrogens and aminoglutethemide given alone or in combination with other cemotherapeutic agents will play an increasing role in the therapy of breast cancer.",
author = "K. Seibert and Lippman, {Marc E}",
year = "1982",
month = "12",
day = "1",
language = "English",
volume = "1",
pages = "735--794",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Hormone receptors in breast cancer

AU - Seibert, K.

AU - Lippman, Marc E

PY - 1982/12/1

Y1 - 1982/12/1

N2 - Many advance have been made in the field of steroid receptor science and its application to new treatment approaches. The gaps in our knowledge of receptor mechanisms have narrowed over the past decade. Some gaps remain to be bridged, as, for example, in the area of nuclear acceptor sites for ER. The total import and role of some receptors, such as prolactin and vitamin D receptors, have yet to be clarified. The DCC assay remains the most practical method for the clinical evaluation of ER and PR status in samples from most postmenopausal women. Samples from premenopausal patients, or patients on tamoxifen therapy, should be evaluated by means of a suitable exchange assay, such as the hydroxylapatite method. Histochemical assays, while more rapid and convenient than the standard DCC or hydroxylapatite assay, have not been fully standardized and have not yet been proved to be a reliable alternative to more conventional techniques. However, they offer promise for a more convenient method of receptor evaluation in the future. The ER and PR status of a tumour, while not absolutely predictive, may serve as an aid in planning treatment for breast cancer patients. ER-negative patients do not benefit significantly from endocrine therapy, while approximately 50 per cent of patients with ER-positive tumours respond to hormonal manipulation. Hyposectomy and adrenalectomy are not largely historical therapies. Presently, endocrine therapies should be used selectively and with good judgement. Tamoxifen, other promising antioestrogens and aminoglutethemide given alone or in combination with other cemotherapeutic agents will play an increasing role in the therapy of breast cancer.

AB - Many advance have been made in the field of steroid receptor science and its application to new treatment approaches. The gaps in our knowledge of receptor mechanisms have narrowed over the past decade. Some gaps remain to be bridged, as, for example, in the area of nuclear acceptor sites for ER. The total import and role of some receptors, such as prolactin and vitamin D receptors, have yet to be clarified. The DCC assay remains the most practical method for the clinical evaluation of ER and PR status in samples from most postmenopausal women. Samples from premenopausal patients, or patients on tamoxifen therapy, should be evaluated by means of a suitable exchange assay, such as the hydroxylapatite method. Histochemical assays, while more rapid and convenient than the standard DCC or hydroxylapatite assay, have not been fully standardized and have not yet been proved to be a reliable alternative to more conventional techniques. However, they offer promise for a more convenient method of receptor evaluation in the future. The ER and PR status of a tumour, while not absolutely predictive, may serve as an aid in planning treatment for breast cancer patients. ER-negative patients do not benefit significantly from endocrine therapy, while approximately 50 per cent of patients with ER-positive tumours respond to hormonal manipulation. Hyposectomy and adrenalectomy are not largely historical therapies. Presently, endocrine therapies should be used selectively and with good judgement. Tamoxifen, other promising antioestrogens and aminoglutethemide given alone or in combination with other cemotherapeutic agents will play an increasing role in the therapy of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020352290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020352290&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0020352290

VL - 1

SP - 735

EP - 794

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -